COLL vs SLB · P/E 17, rev $181.9M vs P/E 12, rev $35.71B
Collegium Pharmaceutical Inc (COLL) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported SLB revenue for 2025-12-31 was $35.71B. Net income was $3.37B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the COLL and SLB stock pages for the full models.
Not investment advice.